Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | KDM1A | O60341 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.44 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.44 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102214 | 1.00 | CYP2D6 (0.55) | CYP2D6HIF1ALMNAKMT2AL3MBTL1 | |
| SCHEMBL102213 | 1.00 | CYP2D6 (0.55) | CYP2D6HIF1ALMNAKMT2AL3MBTL1 | |
| SCHEMBL14239488 | 0.93 | CYP2D6 (0.50) | CYP2D6HIF1ALMNAKMT2AL3MBTL1 | |
| SCHEMBL7014879 | 0.93 | CYP2D6 (0.50) | CYP2D6HIF1ALMNAKMT2AL3MBTL1 | |
| SCHEMBL21215222 | 0.87 | KDM1A (0.60) | LMNAKMT2AL3MBTL1GFERRAB9A | |
| SCHEMBL12333927 | 0.80 | CYP2D6 (0.61) | CYP2D6HIF1ALMNAL3MBTL1RAB9A | |
| SCHEMBL10092621 | 0.79 | KDM1A (0.54) | LMNAKMT2AL3MBTL1GFERRAB9A | |
| SCHEMBL21215275 | 0.78 | RAB9A (0.48) | LMNAKMT2AL3MBTL1GFERRAB9A | |
| SCHEMBL1269960 | 0.77 | KDM1A (0.52) | LMNAKMT2AL3MBTL1GFERRAB9A | |
| SCHEMBL8271836 | 0.77 | KDM1A (0.52) | LMNAKMT2AL3MBTL1GFERRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-09-14 | — | — | US | disclosed |
| US-20170121342-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM | 2017-05-04 | — | — | US | disclosed |
| US-9481692-B2 | Heterocyclic modulators of HIF activity for treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-11-01 | — | — | US | disclosed |
| US-20150252058-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM | 2015-09-10 | — | — | US | disclosed |
| US-9115120-B2 | Heterocyclic modulators of HIF activity for treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMS (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-9018380-B2 | Heterocyclic modulators of HIF activity for treatment of disease | Boar of Regents, The University of Texas System (US) | 2015-04-28 | — | — | US | disclosed |
| US-8883827-B2 | Azole derivatives as WTN pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2014-11-11 | — | — | US | disclosed |
| US-8883827-B2 | Azole derivatives as WTN pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2014-11-11 | — | — | US | disclosed |
| US-8865736-B2 | Antibacterial agents | Biota Scientific Pty Ltd (AU) | 2014-10-21 | — | — | US | disclosed |
| US-20140066424-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140057914-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center (US) | 2014-02-27 | — | — | US | disclosed |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-03-21 | — | — | US | disclosed |
| US-20120208828-A1 | Azole Derivatives as WTN Pathway Inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2012-08-16 | — | — | US | disclosed |
| US-20120208828-A1 | Azole Derivatives as WTN Pathway Inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2012-08-16 | — | — | US | disclosed |
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-05-17 | — | — | US | disclosed |
| WO-2010139966-A1 | AZOLE DERIVATIVES AS WTN PATHWAY INHIBITORS | OSLO UNIVERSITY HOSPITAL HF (NO) | 2010-12-09 | — | — | WO | disclosed |
| US-7432278-B2 | Dicationic imidazo[1,2-a]pyridines and 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridines as antiprotozoal agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, ARG1 | CYP2D6 887/4885HIF1A 460/4885LMNA 3250/4885 |
| US-20120208828-A1 | Azole Derivatives as WTN Pathway Inhibitors | WNT1, AXIN2, WNT3 | CYP2D6 1895/4885HIF1A 2092/4885LMNA 1015/4885 |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | CYP2D6 337/4885HIF1A 985/4885LMNA 1817/4885 |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | ALK, ARG1, ROS1 | CYP2D6 941/4885HIF1A 609/4885LMNA 2877/4885 |
| US-20140057914-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | HIF1AN, HIF1A, EGLN3 | CYP2D6 2361/4885HIF1A 2/4885LMNA 3216/4885 |
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | HDAC6, HDAC1, HDAC3 | CYP2D6 2976/4885HIF1A 3281/4885LMNA 4144/4885 |
| US-20140066424-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | HIF1AN, HIF1A, EGLN3 | CYP2D6 2361/4885HIF1A 2/4885LMNA 3216/4885 |
| US-20150252058-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | HIF1AN, HIF1A, EGLN3 | CYP2D6 2361/4885HIF1A 2/4885LMNA 3216/4885 |
| US-20170121342-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | HIF1AN, HIF1A, EGLN3 | CYP2D6 2361/4885HIF1A 2/4885LMNA 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.